Open Access Open Access  Restricted Access Subscription Access

A Crucial Parameters of Polio Vaccine Include Indications, Mechanism of Action, Administration, Adverse Effects and Contra Indications

Srinivas G., Ramanjaneyulu D.V., Muralinath E., Guruprasad M., Sravani Pragna K., Manjari P., Sony Sharlet E., T. Nikhil, V. Yaswanth Sai, D. Kusuma Latha, Ch. Ramya Sudha, K. Sridevi, D. Gokul Shiva Balaji

Abstract


Poliomyelitis is a highly infectious viral illness that can result in permanent disability. Global vaccination efforts have decreased in a drastical manner the incidence of polio, bringing the disease to the brink of elimination. Even though the oral polio vaccination has a rare risk of paralysis, it is nonetheless an essential tool in many regions of the world due to its low cost and simplicity of administration. In contrast, the inactivated polio vaccine is used in an exclusive manner in countries along with adequate sanitation infrastructure, including the United States, where the risk of vaccine-derived poliovirus is minimized to the maximum extent.Both oral and inactivated polio vaccines' modes of action, routes of administration, formulations, side effects, and patient eligibility are explained in this activity. Vaccination continues to be a top priority for global public health due to the spread of vaccine-derived poliovirus and the continuous transmission of wild-type polio in Afghanistan and Pakistan. The interprofessional healthcare team plays a crucial role in achieving the eradication aim by guaranteeing mass vaccination and keeping an eye out for side effects.


Full Text:

PDF

References


Devaux, C. A., Pontarotti, P., Levasseur, A., Colson, P., & Raoult, D. (2023). Is it time to switch to a formulation other than the live attenuated poliovirus vaccine to prevent poliomyelitis? Frontiers in Public Health, 11, 1284337. https://doi.org/10.3389/fpubh.2023.1284337

Centers for Disease Control and Prevention. (2009). Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination. Morbidity and Mortality Weekly Report, 58(30), 829–830.

Tzeng, S. Y., McHugh, K. J., Behrens, A. M., Rose, S., Sugarman, J. L., Ferber, S., Langer, R., & Jaklenec, A. (2018). Stabilized single-injection inactivated polio vaccine elicits a strong neutralizing immune response. Proceedings of the National Academy of Sciences, 115(23), E5269–E5278. https://doi.org/10.1073/pnas.1805445115

Irwin-Weyant, M. E., & Boggs, S. R. (2023). Polio: Recognition of a reemerging infection. Pediatrics in Review, 44(7), 419–421. https://doi.org/10.1542/pir.2022-005971

Freedman, D. O., & Chen, L. H. (2019). Vaccines for international travel. Mayo Clinic Proceedings, 94(11), 2314–2339. https://doi.org/10.1016/j.mayocp.2019.03.032

Kidd, S., Clark, T., Routh, J., Cineas, S., Bahta, L., Brooks, O. (2023). Use of inactivated polio vaccine among U.S. adults: Updated recommendations of the Advisory Committee on Immunization Practices—United States, 2023. Morbidity and Mortality Weekly Report, 72(49), 1327–1330. https://doi.org/10.15585/mmwr.mm7249a3

Centers for Disease Control and Prevention. (2001). Global progress toward laboratory containment of wild polioviruses, June 2001. Morbidity and Mortality Weekly Report, 50(29), 620–623.

Feldstein, L. R., Mariat, S., Gacic-Dobo, M., Diallo, M. S., Conklin, L. M., & Wallace, A. S. (2017). Global routine vaccination coverage, 2016. Morbidity and Mortality Weekly Report, 66(45), 1252–1255. https://doi.org/10.15585/mmwr.mm6645a3

Fortunato, F., Martinelli, D., Lopalco, P. L., & Prato, R. (2022). Safety evaluation of the DTaP5-IPV-Hib-HepB vaccine: A review. Expert Opinion on Drug Safety, 21(3), 295–302. https://doi.org/10.1080/14740338.2022.2022901

Cooper, L. V., Erbeto, T. B., Danzomo, A. A., Abdullahi, H. W., Boateng, K., Adamu, U. S., Shuaib, F., Modjirom, N., Gray, E. J., Bandyopadhyay, A. S., Zipursky, S., Okiror, S. O., Grassly, N. C., & Blake, I. M. (2024). Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: A case-control study. The Lancet Infectious Diseases, 24(4), 427–436. https://doi.org/10.1016/S1473-3099(23)00713-4

Platt, L. R., Estívariz, C. F., & Sutter, R. W. (2014). Vaccine-associated paralytic poliomyelitis: A review of the epidemiology and estimation of the global burden. Journal of Infectious Diseases, 210(Suppl 1), S380–S389. https://doi.org/10.1093/infdis/jiu184

Geiger, K., Stehling-Ariza, T., Bigouette, J. P., Bennett, S. D., Burns, C. C., Quddus, A., Wassilak, S. G. F., & Bolu, O. (2024). Progress toward

poliomyelitis eradication—Worldwide, January 2022–December 2023. Morbidity and Mortality Weekly Report, 73(19), 441–446. https://doi.org/10.15585/mmwr.mm7319a1

Anselem, O., Parat, S., Théau, A., Floret, D., Tsatsaris, V., Goffinet, F., & Launay, O. (2014). [Vaccination and pregnancy]. La Presse Médicale, 43(6 Pt 1), 715–721. https://doi.org/10.1016/j.lpm.2013.08.010

Arora, M., & Lakshmi, R. (2021). Vaccines—Safety in pregnancy. Best Practice & Research Clinical Obstetrics & Gynaecology, 76, 23–40. https://doi.org/10.1016/j.bpobgyn.2021.04.002

World Health Organization. (2014). Polio vaccines: WHO position paper, January 2014. Weekly Epidemiological Record, 89(9), 73–92. https://apps.who.int/iris/handle/10665/242541


Refbacks

  • There are currently no refbacks.